Jeffrey Eisele - Net Worth and Insider Trading
Jeffrey Eisele Net Worth
The estimated net worth of Jeffrey Eisele is at least $1 Million dollars as of 2025-05-03. Jeffrey Eisele is the Chief Development Officer of Apellis Pharmaceuticals Inc and owns about 55,312 shares of Apellis Pharmaceuticals Inc (APLS) stock worth over $1 Million. Details can be seen in Jeffrey Eisele's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jeffrey Eisele has not made any transactions after 2025-01-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Jeffrey Eisele
Jeffrey Eisele Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jeffrey Eisele owns 1 companies in total, including Apellis Pharmaceuticals Inc (APLS) .
Click here to see the complete history of Jeffrey Eisele’s form 4 insider trades.
Insider Ownership Summary of Jeffrey Eisele
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals Inc | 2025-01-29 | See Remarks |
Jeffrey Eisele Latest Holdings Summary
Jeffrey Eisele currently owns a total of 1 stock. Jeffrey Eisele owns 55,312 shares of Apellis Pharmaceuticals Inc (APLS) as of January 29, 2025, with a value of $1 Million.
Latest Holdings of Jeffrey Eisele
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals Inc | 2025-01-29 | 55,312 | 20.34 | 1,125,046 |
Holding Weightings of Jeffrey Eisele
Jeffrey Eisele Form 4 Trading Tracker
According to the SEC Form 4 filings, Jeffrey Eisele has made a total of 13 transactions in Apellis Pharmaceuticals Inc (APLS) over the past 5 years, including 0 buys and 13 sells. The most-recent trade in Apellis Pharmaceuticals Inc is the sale of 278 shares on January 29, 2025, which brought Jeffrey Eisele around $8,207.
Insider Trading History of Jeffrey Eisele
- 1
Jeffrey Eisele Trading Performance
Jeffrey Eisele Ownership Network
Ownership Network List of Jeffrey Eisele
Ownership Network Relation of Jeffrey Eisele
Jeffrey Eisele Owned Company Details
What does Apellis Pharmaceuticals Inc do?
Who are the key executives at Apellis Pharmaceuticals Inc?
Jeffrey Eisele is the See Remarks of Apellis Pharmaceuticals Inc. Other key executives at Apellis Pharmaceuticals Inc include See Remarks James George Chopas , General Counsel David O. Watson , and Senior Vice President Mark Jeffrey Delong .
Apellis Pharmaceuticals Inc (APLS) Insider Trades Summary
Over the past 18 months, Jeffrey Eisele made 10 insider transaction in Apellis Pharmaceuticals Inc (APLS) with a net sale of 18,079. Other recent insider transactions involving Apellis Pharmaceuticals Inc (APLS) include a net sale of 244,500 shares made by Pascal Deschatelets , a net sale of 35,769 shares made by David O. Watson , and a net sale of 311,716 shares made by Cedric Francois .
In summary, during the past 3 months, insiders sold 6,115 shares of Apellis Pharmaceuticals Inc (APLS) in total and bought 0 shares, with a net sale of 6,115 shares. During the past 18 months, 982,400 shares of Apellis Pharmaceuticals Inc (APLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 982,400 shares.
Apellis Pharmaceuticals Inc (APLS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Apellis Pharmaceuticals Inc Insider Transactions
Jeffrey Eisele Mailing Address
Above is the net worth, insider trading, and ownership report for Jeffrey Eisele. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Jeffrey Eisele's mailing address is: Waltham Ma 02451.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
